GB202010573D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB202010573D0
GB202010573D0 GBGB2010573.0A GB202010573A GB202010573D0 GB 202010573 D0 GB202010573 D0 GB 202010573D0 GB 202010573 A GB202010573 A GB 202010573A GB 202010573 D0 GB202010573 D0 GB 202010573D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2010573.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Union Therapeutics AS
Original Assignee
Union Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Therapeutics AS filed Critical Union Therapeutics AS
Priority to GBGB2010573.0A priority Critical patent/GB202010573D0/en
Publication of GB202010573D0 publication Critical patent/GB202010573D0/en
Priority to US17/097,898 priority patent/US11045434B1/en
Priority to AU2021248603A priority patent/AU2021248603A1/en
Priority to MX2022012360A priority patent/MX2022012360A/en
Priority to KR1020227038253A priority patent/KR20230024883A/en
Priority to BR112022019521A priority patent/BR112022019521A2/en
Priority to US17/995,053 priority patent/US20230190685A1/en
Priority to US17/995,079 priority patent/US20230147683A1/en
Priority to CA3173163A priority patent/CA3173163A1/en
Priority to MX2022012359A priority patent/MX2022012359A/en
Priority to CN202180036954.6A priority patent/CN115701984A/en
Priority to EP21715583.7A priority patent/EP4125805A1/en
Priority to PCT/EP2021/058047 priority patent/WO2021198116A1/en
Priority to JP2022560369A priority patent/JP2023520542A/en
Priority to CN202180035793.9A priority patent/CN115701983A/en
Priority to JP2022560085A priority patent/JP2023520229A/en
Priority to KR1020227038248A priority patent/KR20230020952A/en
Priority to AU2021247378A priority patent/AU2021247378A1/en
Priority to IL296898A priority patent/IL296898A/en
Priority to IL296909A priority patent/IL296909A/en
Priority to BR112022019519A priority patent/BR112022019519A2/en
Priority to EP21715582.9A priority patent/EP4125804A1/en
Priority to PCT/EP2021/058046 priority patent/WO2021198115A1/en
Priority to CA3172166A priority patent/CA3172166A1/en
Priority to US17/330,067 priority patent/US11324708B1/en
Priority to US17/723,079 priority patent/US20220323384A1/en
Ceased legal-status Critical Current

Links

GBGB2010573.0A 2020-04-01 2020-07-09 Formulation Ceased GB202010573D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB2010573.0A GB202010573D0 (en) 2020-07-09 2020-07-09 Formulation
US17/097,898 US11045434B1 (en) 2020-04-01 2020-11-13 Niclosamide formulations for treating disease
CA3172166A CA3172166A1 (en) 2020-04-01 2021-03-26 Formulation
PCT/EP2021/058047 WO2021198116A1 (en) 2020-04-01 2021-03-26 Formulation
JP2022560085A JP2023520229A (en) 2020-04-01 2021-03-26 pharmaceutical formulation
KR1020227038253A KR20230024883A (en) 2020-04-01 2021-03-26 formulation
BR112022019521A BR112022019521A2 (en) 2020-04-01 2021-03-26 FORMULATION
US17/995,053 US20230190685A1 (en) 2020-04-01 2021-03-26 Formulation
US17/995,079 US20230147683A1 (en) 2020-04-01 2021-03-26 Treatment
CA3173163A CA3173163A1 (en) 2020-04-01 2021-03-26 Treatment
MX2022012359A MX2022012359A (en) 2020-04-01 2021-03-26 Formulation.
CN202180036954.6A CN115701984A (en) 2020-04-01 2021-03-26 Treatment of
EP21715583.7A EP4125805A1 (en) 2020-04-01 2021-03-26 Formulation
AU2021248603A AU2021248603A1 (en) 2020-04-01 2021-03-26 Treatment
JP2022560369A JP2023520542A (en) 2020-04-01 2021-03-26 therapeutic drug
CN202180035793.9A CN115701983A (en) 2020-04-01 2021-03-26 Formulations
MX2022012360A MX2022012360A (en) 2020-04-01 2021-03-26 Treatment.
KR1020227038248A KR20230020952A (en) 2020-04-01 2021-03-26 therapy
AU2021247378A AU2021247378A1 (en) 2020-04-01 2021-03-26 Formulation
IL296898A IL296898A (en) 2020-04-01 2021-03-26 Treatment
IL296909A IL296909A (en) 2020-04-01 2021-03-26 Formulation
BR112022019519A BR112022019519A2 (en) 2020-04-01 2021-03-26 TREATMENT
EP21715582.9A EP4125804A1 (en) 2020-04-01 2021-03-26 Treatment
PCT/EP2021/058046 WO2021198115A1 (en) 2020-04-01 2021-03-26 Treatment
US17/330,067 US11324708B1 (en) 2020-04-01 2021-05-25 Niclosamide formulations for treating disease
US17/723,079 US20220323384A1 (en) 2020-04-01 2022-04-18 Niclosamide formulations for treating disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2010573.0A GB202010573D0 (en) 2020-07-09 2020-07-09 Formulation

Publications (1)

Publication Number Publication Date
GB202010573D0 true GB202010573D0 (en) 2020-08-26

Family

ID=72140074

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2010573.0A Ceased GB202010573D0 (en) 2020-04-01 2020-07-09 Formulation

Country Status (1)

Country Link
GB (1) GB202010573D0 (en)

Similar Documents

Publication Publication Date Title
GB202007546D0 (en) Formulation
GB201902551D0 (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
GB2599912B (en) New formulation
GB2595300B (en) Novel Formulation
GB2595453B (en) Novel Formulation
IL307849A (en) Sotorasib formulation
IL308046A (en) Alpelisib formulation
GB202108165D0 (en) Formulation
GB202107439D0 (en) Formulation
GB202107203D0 (en) Formulation
GB202103970D0 (en) Formulation
GB202102636D0 (en) Formulation
GB202102408D0 (en) Formulation
GB202016274D0 (en) Formulation
GB202010573D0 (en) Formulation
GB202006008D0 (en) Aerosolisable formulation
GB202005340D0 (en) Formulation
GB202003048D0 (en) Formulation
IL305977A (en) Formulation comprising ceralasertib
GB202115303D0 (en) New formulation
GB202108181D0 (en) New formulation
GB202007620D0 (en) Novel formulation
GB202318884D0 (en) Formulation
GB202316857D0 (en) Cannabinoid-based formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)